UNIGE document Scientific Article
previous document  unige:74558  next document
add to browser collection

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report

Agnandji, Selidji T.
CollaborationWith : Yerly Ferrillo, Sabine / Auderset, Floriane / Combescure, Christophe / Desmeules, Jules Alexandre / Finckh, Axel / Goncalves Cabecinhas, Ana Rita / Kaya, Gurkan / Lemaitre, Barbara / Matthey, Alain / Kaiser, Laurent / Siegrist, Claire-Anne
Published in New England Journal of Medicine. 2016, vol. 374, no. 17, p. 1647-1660
Abstract The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.
PMID: 25830326
Full text
Article (Published version) (787 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Groupe Laurent Kaiser (virologie clinique) (668)
Centre de vaccinologie et d'immunologie néonatale (177)
Mécanisme de l'inflammation articulaire (44)
Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Epidémiologie clinique (115)
(ISO format)
AGNANDJI, Selidji T. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report. In: New England Journal of Medicine, 2016, vol. 374, n° 17, p. 1647-1660. https://archive-ouverte.unige.ch/unige:74558

380 hits



Deposited on : 2015-08-10

Export document
Format :
Citation style :